Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor-derived anti-leukemia cytotoxic t lymphocytes
- Development stage
- Unknown
- Lead developer
- IRCCS San Matteo Foundation
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived anti-leukemia cytotoxic T lymphocytes (CTLs) are *ex vivo*-expanded T cells obtained from a hematopoietic stem cell (HSC) donor, specifically stimulated and selected for reactivity against leukemia-associated antigens. These CTLs are predominantly CD3+/CD8+ T cells with a memory/terminal activated phenotype and are infused after haploidentical HSC transplantation to recognize and lyse leukemia blasts in pediatric patients with high-risk acute leukemia. This adoptive cell therapy aims to prevent or reduce relapse by enhancing the graft-versus-leukemia (GVL) effect while minimizing the risk of graft-versus-host disease (GVHD), as the CTLs are selected for anti-leukemia specificity and reduced alloreactivity. The product is manufactured under Good Manufacturing Practice and is being investigated in early-phase clinical trials (notably the Leuk-001 study) for children post-haploidentical hematopoietic cell transplant[1][2][3][4][6].
- Other names
- donor-derived anti-leukemia CTLs
02
Targets
MiHA (Minor histocompatibility antigen)
Beyond the preview
Go deeper on donor-derived anti-leukemia cytotoxic t lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor-derived anti-leukemia cytotoxic t lymphocytes.